590
Participants
Start Date
December 17, 2017
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Guardant Health ct-DNA LUNAR assay
Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
RECRUITING
Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco
RECRUITING
San Francisco VA Medical Center, San Francisco
RECRUITING
University of California, San Francisco, San Francisco
Collaborators (1)
Northern California Institute of Research and Education
OTHER
Guardant Health, Inc.
INDUSTRY
University of California, San Francisco
OTHER